113 related articles for article (PubMed ID: 27477900)
1. BARD1 splice variants display mislocalization in breast cancer cells and can alter the apoptotic response to cisplatin.
Marzec KA; Martino-Echarri E; Irminger-Finger I; Henderson BR
Cancer Lett; 2016 Oct; 381(1):149-55. PubMed ID: 27477900
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression.
Wiener D; Gajardo-Meneses P; Ortega-Hernández V; Herrera-Cares C; Díaz S; Fernández W; Cornejo V; Gamboa J; Tapia T; Alvarez C; Carvallo P
Breast Cancer Res Treat; 2015 Oct; 153(3):669-78. PubMed ID: 26395808
[TBL] [Abstract][Full Text] [Related]
3. BARD1 translocation to mitochondria correlates with Bax oligomerization, loss of mitochondrial membrane potential, and apoptosis.
Tembe V; Henderson BR
J Biol Chem; 2007 Jul; 282(28):20513-22. PubMed ID: 17510055
[TBL] [Abstract][Full Text] [Related]
4. The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function.
Tembe V; Martino-Echarri E; Marzec KA; Mok MT; Brodie KM; Mills K; Lei Y; DeFazio A; Rizos H; Kettle E; Boadle R; Henderson BR
Cell Signal; 2015 Sep; 27(9):1763-71. PubMed ID: 26022179
[TBL] [Abstract][Full Text] [Related]
5. BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention.
Fabbro M; Schuechner S; Au WW; Henderson BR
Exp Cell Res; 2004 Aug; 298(2):661-73. PubMed ID: 15265711
[TBL] [Abstract][Full Text] [Related]
6. Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1.
Rodriguez JA; Schüchner S; Au WW; Fabbro M; Henderson BR
Oncogene; 2004 Mar; 23(10):1809-20. PubMed ID: 14647430
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.
Zhu Y; Liu Y; Zhang C; Chu J; Wu Y; Li Y; Liu J; Li Q; Li S; Shi Q; Jin L; Zhao J; Yin D; Efroni S; Su F; Yao H; Song E; Liu Q
Nat Commun; 2018 Apr; 9(1):1595. PubMed ID: 29686231
[TBL] [Abstract][Full Text] [Related]
8. BARD1: an independent predictor of survival in non-small cell lung cancer.
Zhang YQ; Bianco A; Malkinson AM; Leoni VP; Frau G; De Rosa N; André PA; Versace R; Boulvain M; Laurent GJ; Atzori L; Irminger-Finger I
Int J Cancer; 2012 Jul; 131(1):83-94. PubMed ID: 21815143
[TBL] [Abstract][Full Text] [Related]
9. Nuclear targeting and cell cycle regulatory function of human BARD1.
Schüchner S; Tembe V; Rodriguez JA; Henderson BR
J Biol Chem; 2005 Mar; 280(10):8855-61. PubMed ID: 15632137
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel alternatively spliced BRCA1-associated RING domain (BARD1) messenger RNAs in human peripheral blood lymphocytes and in sporadic breast cancer tissues.
Lombardi G; Falaschi E; Di Cristofano C; Naccarato AG; Sensi E; Aretini P; Roncella M; Bevilacqua G; Caligo MA
Genes Chromosomes Cancer; 2007 Sep; 46(9):791-5. PubMed ID: 17497650
[TBL] [Abstract][Full Text] [Related]
11. Characterization of BARD1 targeting and dynamics at the centrosome: the role of CRM1, BRCA1 and the Q564H mutation.
Brodie KM; Mok MTS; Henderson BR
Cell Signal; 2012 Feb; 24(2):451-459. PubMed ID: 21982881
[TBL] [Abstract][Full Text] [Related]
12. BARD1 expression predicts outcome in colon cancer.
Sporn JC; Hothorn T; Jung B
Clin Cancer Res; 2011 Aug; 17(16):5451-62. PubMed ID: 21693656
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic BARD1 isoforms expressed in gynecological cancers.
Li L; Ryser S; Dizin E; Pils D; Krainer M; Jefford CE; Bertoni F; Zeillinger R; Irminger-Finger I
Cancer Res; 2007 Dec; 67(24):11876-85. PubMed ID: 18089818
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.
Wu JY; Vlastos AT; Pelte MF; Caligo MA; Bianco A; Krause KH; Laurent GJ; Irminger-Finger I
Int J Cancer; 2006 Mar; 118(5):1215-26. PubMed ID: 16152612
[TBL] [Abstract][Full Text] [Related]
15. BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export.
Fabbro M; Rodriguez JA; Baer R; Henderson BR
J Biol Chem; 2002 Jun; 277(24):21315-24. PubMed ID: 11925436
[TBL] [Abstract][Full Text] [Related]
16. Nuclear-cytoplasmic translocation of BARD1 is linked to its apoptotic activity.
Jefford CE; Feki A; Harb J; Krause KH; Irminger-Finger I
Oncogene; 2004 Apr; 23(20):3509-20. PubMed ID: 15077185
[TBL] [Abstract][Full Text] [Related]
17. Antagonizing functions of BARD1 and its alternatively spliced variant BARD1δ in telomere stability.
Pilyugin M; André PA; Ratajska M; Kuzniacka A; Limon J; Tournier BB; Colas J; Laurent G; Irminger-Finger I
Oncotarget; 2017 Feb; 8(6):9339-9353. PubMed ID: 28030839
[TBL] [Abstract][Full Text] [Related]
18. Differential modulation of BRCA1 and BARD1 nuclear localisation and foci assembly by DNA damage.
Brodie KM; Henderson BR
Cell Signal; 2010 Feb; 22(2):291-302. PubMed ID: 19796682
[TBL] [Abstract][Full Text] [Related]
19. Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1.
Dizin E; Irminger-Finger I
Int J Biochem Cell Biol; 2010 May; 42(5):693-700. PubMed ID: 20060929
[TBL] [Abstract][Full Text] [Related]
20. Identification of BARD1 splice-isoforms involved in human trophoblast invasion.
Li L; Cohen M; Wu J; Sow MH; Nikolic B; Bischof P; Irminger-Finger I
Int J Biochem Cell Biol; 2007; 39(9):1659-72. PubMed ID: 17556008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
